Sten Cell Gene Therapy of Breast Cancer

乳腺癌的 Sten 细胞基因治疗

基本信息

批准号：
8468579
负责人：
ANDRE Michael LIEBER
金额：
$ 29.52万
依托单位：
UNIVERSITY OF WASHINGTON
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
起止时间：
2009-07-22 至 2014-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8468579
关键词：
Adverse effects Aniline Mustard Antibodies Apoptosis Beta-glucuronidase Biodistribution Birth Blood Vessels Bone Marrow Bone Marrow Cells Bone Marrow Stem Cell Bone Marrow Transplantation Breast Cancer Model Breast Cancer Treatment Breast Carcinoma Cancer Control Cancer Patient Cell Count Cell Transplants Cells Collagen Cytostatics Cytotoxic agent Data Disease Dose Doxycycline Drug Controls ERBB2 gene Effector Cell Engraftment Fluorescent Dyes Gene Delivery Gene Expression Gene Expression Profile Gene-Modified Genes Genetic Glucuronides Goals Growth Factor Health Hematopoietic Neoplasms Hematopoietic stem cells Heterogeneity Home environment Homing Hormones Human Hypoxia Image Immune Immune Cell Activation Immune response Immunity Immunosuppressive Agents Improve Access In Vitro Inbred BALB C Mice Injection of therapeutic agent Intercellular Fluid Intravenous Investigational Therapies Laminin Lentivirus Vector Ligaments Liposomes Malignant Epithelial Cell Malignant Neoplasms Mediating Membrane Messenger RNA Methods MicroRNAs Modeling Molecular Profiling Mus Myelogenous Myeloid Cells Neoplasm Metastasis Nutrient Oncogenes Patients Pharmaceutical Preparations Population Preparation Procedures Prodrugs Proteins Publishing Rattus Recruitment Activity Regimen Regulatory T-Lymphocyte Relaxin Role Route Safety Series Source Staging Stem cell transplant Stem cells Stomas Subfamily lentivirinae Suicide Suspension substance Suspensions System T-Lymphocyte Testing Therapeutic Therapeutic Effect Tissues Transgenes Transgenic Mice Transplantation Treatment Efficacy Tumor-Derived Vaccination Variant Viral Virus antitumor agent base cancer cell cell stroma cell type chemotherapy clinically relevant cytokine density dosage extracellular gene therapy genetically modified cells in vivo irradiation killings lymph nodes macrophage malignant breast neoplasm mouse model nanoparticle neoplastic cell novel strategies peptide hormone pressure prevent progenitor promoter reconstitution therapeutic transgene tool transgene expression tumor tumor growth tumor microenvironment vector

项目摘要

DESCRIPTION (provided by applicant): Although tumor-specific immune cells are found in stage IV breast cancer patients, they are not able to control tumor growth. This is in part due to tumor stroma that tightly surrounds tumor nests. Tumor stroma contributes to immune evasion of breast cancer in at least two critical ways; by creating a physical barrier that prevents direct contact between tumor infiltrating immune cells and malignant cells, and by producing immunosuppressive cytokines that directly block activation of immune cells and/or attract/activate immuno-suppressive cells such as regulatory T-cells. In this proposal, we will test a new stem cell gene therapy approach that targets tumor stroma cells with the goal to enable existing immune cells to control tumor growth. The specific tumor microenvironment as well as cytokines/growth factors produced by tumor cells trigger differentiation of tumor-infiltrating hematopoietic tumor cells into a unique type of macrophages (so called tumor-associated macrophages -"TAMs"), with a gene expression signature that is distinct from that of tissue macrophages and myeloid cells. TAMs are the prevalent stroma cell type and the number of TAMs directly correlates with breast cancer malignancy. Our central hypotheses are that i) bone marrow derived TAM progenitors can be used to deliver therapeutic transgenes to the tumor stroma, ii) the unique mRNA and microRNA expression profile of TAMs can be used to construct TAM-specific transgene expression systems, and iii) that drug controlled, transgene mediated killing of stroma cells and/or degradation of stroma protein enable long-term control of cancer. We provide a series of preliminary data that support the feasibility of our strategy. We will test our hypotheses in a mouse model of breast cancer involving rat neu-transgenic mice (neu-tg) and syngeneic mammary carcinoma cells (MMC). Key findings will be validated in a second breast cancer model that involves 4T1 cells and BALB/c mice.

描述（由申请人提供）：尽管在IV期乳腺癌患者中发现了肿瘤特异性的免疫细胞，但他们无法控制肿瘤的生长。这部分是由于肿瘤基质紧密围绕肿瘤巢。肿瘤基质以至少两种关键方式有助于免疫逃避乳腺癌。通过创建一个物理屏障，该物理屏障可以防止肿瘤浸润的免疫细胞和恶性细胞之间的直接接触，并产生免疫抑制性细胞因子，该细胞因子直接阻止免疫细胞的激活和/或吸引/或吸引/激活免疫抑制细胞，例如调节性T细胞。在此提案中，我们将测试一种新的干细胞基因治疗方法，该方法靶向肿瘤基质细胞，其目标是使现有的免疫细胞能够控制肿瘤的生长。肿瘤细胞产生的特定肿瘤微环境以及细胞因子/生长因子会引发肿瘤浸润造血肿瘤细胞的分化成独特的巨噬细胞（所谓的肿瘤相关巨噬细胞-TAMS-“ TAMS”），具有与组织型和Mocoid oiloid scoloid and Moioles and Myeroioles and Myereeleeleeleeleeleeleeleeleeleeleroiles and Moloiles and Myereloiles and Myereeloiles and Myereeleeleeleeleeleeleeleeleeleeleeleeleeleeleeleeleeleeleeleeleeleeleeloil eeleeleeleeleeloil andereeleeleeleeleeleeleeleeleeleeleeleeleel eLloid。 TAM是普遍的基质细胞类型，TAM的数量与乳腺癌恶性肿瘤直接相关。我们的中心假设是i）骨髓衍生的TAM祖细胞可用于向肿瘤基质传递治疗性转基因，ii）ii）TAM的独特mRNA和microRNA表达谱可用于构建TAM特异性转基因表达系统，iii），该药物控制的，跨二聚体介导的细胞瘤杀伤型细胞和脱发型造型型造影剂造成了茎的造成的蛋白酶，并构成了造膜蛋白酶。我们提供一系列支持我们战略可行性的初步数据。我们将在涉及大鼠NEU-转基因小鼠（NEU-TG）和合成性乳腺癌细胞（MMC）的乳腺癌的小鼠模型中测试我们的假设。主要发现将在涉及4T1细胞和BALB/C小鼠的第二个乳腺癌模型中进行验证。